arrow_back Back to App

Home Treatment for Alpha-1 Antitrypsin Deficiency: New Medicare Rules

This new act aims to make it easier for individuals with Alpha-1 Antitrypsin Deficiency to receive treatment at home under Medicare. This means patients can get necessary infusion therapies in the comfort of their own homes, potentially improving their quality of life and reducing the burden of medical facility visits. The act also establishes payment rules for infusion kits and nursing services.
Key points
Medicare will cover the costs of Alpha-1 Antitrypsin Deficiency treatment (augmentation therapy) administered at home.
Payments will include intravenous administration kits and up to 2 hours of nursing services provided at home by qualified suppliers.
The changes will take effect on January 1, 2027, and apply to individuals enrolled in both Medicare Parts A and B who are not in a Medicare Advantage plan.
article Official text account_balance Process page
Introduced
Citizen Poll
No votes cast
Additional Information
Print number: 119_HR_2343
Sponsor: Rep. Salazar, Maria Elvira [R-FL-27]
Process start date: 2025-03-25
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

John W. Walsh Alpha-1 Home Infusion Act of 2025

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_HR_2343.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2025-03-25.

What are the main provisions?

Key points include:

  • Medicare will cover the costs of Alpha-1 Antitrypsin Deficiency treatment (augmentation therapy) administered at home.
  • Payments will include intravenous administration kits and up to 2 hours of nursing services provided at home by qualified suppliers.
  • The changes will take effect on January 1, 2027, and apply to individuals enrolled in both Medicare Parts A and B who are not in a Medicare Advantage plan.
What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Salazar, Maria Elvira [R-FL-27].

What is the latest detailed status?

The latest detailed status is: Introduced in House

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-22.

CATEGORIES

Health Benefits